antibiotics

Coalition of drugmakers to unveil $1B venture to pursue antibiotics
Coalition of drugmakers to unveil $1B venture to pursue antibiotics
Beckers Hospital Review
Big Pharma
drug development
antibiotics
innovation
Eli Lilly
Pfizer
Merck
Boehringer Ingelheim
Bayer
CARB-X
Flag link:
Nabriva hit with another FDA setback with complete response letter for antibiotic Contepo
Nabriva hit with another FDA setback with complete response letter for antibiotic Contepo
Fierce Pharma
Nabriva Therapeutics
FDA
Xenleta
antibiotics
Flag link:
Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition
Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition
Xconomy
Melinta Therapeutics
Tetraphase
M&A
antibiotics
Flag link:
As U.S. calls for stateside manufacturing, antibiotic maker Paratek gambles on 'onshoring' effort
As U.S. calls for stateside manufacturing, antibiotic maker Paratek gambles on 'onshoring' effort
Fierce Pharma
drug manufacturing
Paratek
pandemic
COVID-19
antibiotics
Flag link:
As it happened: A bidding war for an antibiotic maker in a market that has ravaged its peers
As it happened: A bidding war for an antibiotic maker in a market that has ravaged its peers
Endpoints
antibiotics
M&A
Tetraphase
AcelRx
Melinta Therapeutics
La Jolla Pharmaceutical
Flag link:
Antibiotic pipeline in peril from coronavirus and incentives system
Antibiotic pipeline in peril from coronavirus and incentives system
Axios
antibiotics
drug development
COVID-19
pandemic
Flag link:
Pfizer, Teva running short on antibiotic azithromycin amid COVID-19 therapy hunt
Pfizer, Teva running short on antibiotic azithromycin amid COVID-19 therapy hunt
Fierce Pharma
Pfizer
Teva Pharmaceutical
drug shortages
azithromycin
COVID-19
antibiotics
Flag link:
Forge, Roche Enter Antibiotic Alliance
Forge, Roche Enter Antibiotic Alliance
Contract Pharma
Roche
Forge Therapeutics
antibiotics
drug development
FG-LpxC LUNG
lung infections
Flag link:
Another antibiotic maker bites the dust, as Tetraphase is swallowed for cheap
Another antibiotic maker bites the dust, as Tetraphase is swallowed for cheap
Endpoints
antibiotics
Tetraphase
M&A
AcelRx
Flag link:
Melinta's Bankruptcy Underlines Problems with the Antibiotics Market
Melinta's Bankruptcy Underlines Problems with the Antibiotics Market
BioSpace
Melinta Therapeutics
bankruptcy
antibiotics
Flag link:
New Antibiotics Face Major Development And Reimbursement Hurdles
New Antibiotics Face Major Development And Reimbursement Hurdles
Forbes
antibiotic resistance
antibiotics
drug-resistant infections
drug development
reimbursement
Flag link:
Certain GSK antibiotic brands are up for sale — report
Certain GSK antibiotic brands are up for sale — report
Endpoints
GSK
antibiotics
Flag link:
Sandoz pledges 'stable' pricing for generics, antibiotics amid COVID-19 supply chain worries
Sandoz pledges 'stable' pricing for generics, antibiotics amid COVID-19 supply chain worries
Fierce Pharma
Sandoz
generics
antibiotics
COVID-19
coronaviruses
Flag link:
Bankrupt antibiotics maker Aradigm turns to old partner/investor for final $3M fire sale
Bankrupt antibiotics maker Aradigm turns to old partner/investor for final $3M fire sale
Endpoints
Grifols
antibiotics
Aradigm
Flag link:
Too Many Antibiotics Prescribed With No Doctor’s Visit, Study Finds
Too Many Antibiotics Prescribed With No Doctor’s Visit, Study Finds
Forbes
antibiotics
physicians
Flag link:
Novo Holdings tweaks fund to take antibiotics deeper into the clinic
Novo Holdings tweaks fund to take antibiotics deeper into the clinic
Fierce Biotech
Novo Holdings
antibiotics
drug development
Flag link:
Antibiotics maker Melinta files for Chapter 11 bankruptcy
Antibiotics maker Melinta files for Chapter 11 bankruptcy
Reuters
Melinta Therapeutics
Chapter 11
bankruptcy
antibiotics
Flag link:
Biopharma has abandoned antibiotic development. Here’s why we did, too.
Biopharma has abandoned antibiotic development. Here’s why we did, too.
Endpoints
Octagon Therapeutics
drug discovery
drug development
antibiotics
Flag link:
With looming superbug crisis, Iterum misses in a key antibiotic trial — and its shares tumble
With looming superbug crisis, Iterum misses in a key antibiotic trial — and its shares tumble
Endpoints
Iterum
sulopenem
antibiotics
clinical trial
antibiotic resistance
Flag link:
Brii bags rights to tuberculosis drug to further antibiotic push
Brii bags rights to tuberculosis drug to further antibiotic push
Fierce Biotech
Brii Biosciences
China
AN2 Therapeutics
tuberculosis
antibiotics
Flag link:

Pages